Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles.

Research output: Contribution to journalArticle


Human papillomavirus type 16 (HPV-16) is a major cause of human cancer. Effective prophylactic vaccines are based on type-specific neutralizing antibodies. A major neutralizing epitope has been defined by the monoclonal antibody H16.V5. To investigate the importance of this epitope for overall immunogenicity of HPV-16, HPV-16 virus-like particles devoid of the H16.V5 epitope were engineered by site-directed mutagenesis of ten non-conserved, surface-exposed residues. Removal of the H16.V5-defined epitope had only a marginal effect on antigenic reactivity with antibodies in sera from infected subjects, but affected immunogenicity in experimental immunization of mice, with reduced induction of both antibody responses and CTL responses.


  • Janka Ryding
  • L Dahlberg
  • M Wallen-Ohman
  • Joakim Dillner
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Microbiology in the medical area
Original languageEnglish
Pages (from-to)792-802
JournalJournal of General Virology
Issue numberPt 3
Publication statusPublished - 2007
Publication categoryResearch

Related research output

Janka Ryding, 2008, Department of Laboratory Medicine, Lund University. 159 p.

Research output: ThesisDoctoral Thesis (compilation)

View all (1)